WHY MOST SUPPLEMENTS FAIL

The Across-the-Category Finding

The 2005 systematic review of randomized hangover-prevention trials looked at every published RCT on every conventional and complementary intervention for alcohol hangover and concluded that no compelling evidence existed for any of them as a clinically reliable treatment ¹. That finding has not been substantially overturned in the two decades since. The hangover-supplement category fails its primary test more often than not.

The interesting question is why. The mechanisms in the published literature are real -- DHM induces ADH and ALDH in animals, NAC restores glutathione precursors, prickly pear lowers inflammatory markers. The pattern is that these mechanisms do not consistently translate from animal models to human supplement formats at the doses that get used. The gap between mechanism and clinical effect is the failure mode the systematic review keeps documenting ². (I had to confront this pattern personally during the testing phase, because it explained why nothing on the retail shelf had worked for me before I started building the formula.)

Failure Mode 1: Under-Dosing

The first failure mode is dose. Most retail supplements use doses that sit substantially below the doses used in the underlying clinical or preclinical research they reference. For DHM, the typical retail dose is 100-300mg per serving against an effective floor (after surface-area conversion and bioavailability haircut) closer to 1,000-1,500mg ³. For NAC, retail doses sit in the hundreds of milligrams against effective hepatoprotective doses in the gram range. The across-the-category failure pattern is well-documented, in the systematic review evidence at least.

For the DHM-specific dose math, see DHM Dose-Response. For why the industry under-doses anyway, see Why Most DHM Supplements Are Under-Dosed.

Failure Mode 2: Weak Mechanisms

The second failure mode is mechanism choice. A lot of products lean on antioxidant blends or vitamin mixtures that do not act on the alcohol metabolism pathway specifically. Antioxidants buffer downstream damage but do not change the rate of acetaldehyde clearance, so they have a fundamental ceiling on how much they can help. Compounds that act upstream (DHM on enzyme induction, for example) have higher ceilings because they intervene before the damage rather than after.

Failure Mode 3: Bioavailability

The third failure mode is bioavailability, particularly for flavonoid-class ingredients with poor native gut absorption. DHM at 4 percent absolute oral bioavailability ³ is the canonical example, but plain glutathione has a similar problem (sub-1 percent), and many polyphenol ingredients that look impressive on a label deliver almost none of the labeled compound to the intracellular compartments where they need to act. Without a delivery-format strategy (lipid nanocarriers, sustained-release tablets, fulvic acid chelation), the labeled dose vastly overstates the functional dose.

What Working Around These Failures Looks Like

The H180 formula was built specifically to avoid all three failure modes: dose DHM at 1,500mg to clear the bioavailability haircut, choose mechanisms that act upstream (DHM enzyme induction) and provide intact downstream antioxidant capacity (SAG), and pair both with a delivery-agent (fulvic acid) that addresses the gut absorption problem. The 2024 NAC-binge-drinker null trial is a useful contrast ⁴: it shows what happens when a mechanistically reasonable ingredient gets dosed in a format that does not match the underlying pharmacokinetics.

What This Page Is Not Claiming

We are not claiming H180 is a hangover cure or that it has been proven superior to other supplements in head-to-head clinical trials. The claim is narrower: most supplements in this category fail for documented structural reasons, and the formula is engineered to avoid those specific failure modes. The failure modes are predictable, adn knowing them is the first step to choosing supplements that actually have a chance of doing what they claim.